Compare · CRL vs ISPC
CRL vs ISPC
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and iSpecimen Inc. (ISPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and ISPC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $16.42B, about 4276.4x ISPC ($3.8M).
- CRL has been more active in the news (13 items in the past 4 weeks vs 7 for ISPC).
- CRL has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- Charles River Laboratories International Inc.
- iSpecimen Inc.
- Price
- -
- -
- Market cap
- $16.42B
- $3.8M
- 1M return
- +14.51%
- -
- 1Y return
- +99.60%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 13
- 7
- Recent ratings
- 25
- 2
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest CRL
- Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.
- Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
- SVP, Finance and CAO Knell Michael Gunnar covered exercise/tax liability with 649 shares, decreasing direct ownership by 5% to 11,203 units (SEC Form 4) (withholding tax)
- Charles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses
- Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.
- SEC Form 10-Q filed by Charles River Laboratories International Inc.
- Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Charles River Laboratories Announces Third-Quarter 2026 Results
- Charles River Leverages Virtual Control Groups in GLP Studies
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
- SEC Form DEFR14A filed by iSpecimen Inc.
- SEC Form PRER14A filed by iSpecimen Inc.
- SEC Form 8-K filed by iSpecimen Inc.
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer